Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Update

Virax Biolabs Group Limited (NASDAQ:VRAX) was the target of a significant increase in short interest during the month of December. As of December 31st, there was short interest totalling 164,900 shares, an increase of 85.5% from the December 15th total of 88,900 shares. Currently, 4.1% of the shares of the stock are sold short. Based on an average daily volume of 1,790,000 shares, the short-interest ratio is currently 0.1 days.

Virax Biolabs Group Stock Performance

Shares of NASDAQ:VRAX opened at $2.07 on Thursday. Virax Biolabs Group has a 52 week low of $0.60 and a 52 week high of $9.00. The firm has a 50 day simple moving average of $2.02 and a 200 day simple moving average of $2.14.

Virax Biolabs Group Company Profile

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name.